TEKLA LIFE SCIENCES INVESTOR (HQL)
$13.62
+0.01
(+0.07%)▲
Insights on Tekla Life Sciences Investors
Vs APO
In the last 1 year, Apollo Global Management Inc - Class A has given 20.1% return, outperforming this stock by 25.9%
Vs KKR
In the last 3 years, KKR & Co. Inc. has given 33.5% return, outperforming this stock by 55.7%
Performance
- $13.50$13.75$13.62
0.88%
Downside
Day's Volatility :1.82%
Upside
0.95%
- $11.94$14.96$13.62
12.33%
Downside
52 Weeks Volatility :20.19%
Upside
8.96%
Returns
| Period | TEKLA LIFE SCIENCES INVESTOR | Russel 2000 | Index (Russel 2000) |
|---|---|---|---|
3 Months | -3.68% | -5.8% | -5.8% |
6 Months | -8.53% | -2.1% | -2.1% |
1 Year | -5.81% | -7.8% | -7.8% |
3 Years | -22.63% | 17.4% | 17.4% |
Highlights
Market Capitalization | 357.7M |
Book Value | $15.5 |
Dividend Share | 1.47 |
Dividend Yield | 9.63% |
Earnings Per Share (EPS) | -4.33 |
PEG Ratio | 0.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -99.04% |
Return On Assets TTM | -0.39% |
Return On Equity TTM | -22.71% |
Revenue TTM | 3.0M |
Revenue Per Share TTM | 0.12 |
Quarterly Revenue Growth YOY | 34.5% |
Gross Profit TTM | 3.0M |
Diluted Eps TTM | -4.33 |
Quarterly Earnings Growth YOY | -0.66 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Tekla Life Sciences Investors is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 TEKLA LIFE SCIENCES INVESTOR | -2.02% | -8.53% | -5.81% | -22.63% | -27.37% |
 Blackstone Inc | 7.68% | 12.57% | -27.06% | 47.01% | 167.61% |
 KKR & Co. L.P. | 10.59% | 15.16% | -4.25% | 72.02% | 142.57% |
 BlackRock, Inc. | 6.5% | -3.42% | 0.78% | 22.89% | 24.73% |
 Apollo Asset Management Inc | 14.72% | 15.54% | 20.06% | 34.29% | 120.35% |
 Brookfield Corp | -0.41% | -5.68% | -5.68% | -5.68% | -5.68% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
TEKLA LIFE SCIENCES INVESTOR | 5.75 | NA | 0.0 | 0.0 | -0.23 | 0.0 | 0.1 | 15.5 |
Blackstone Inc | 107.3 | 107.3 | 1.27 | 4.39 | 0.03 | 0.02 | 0.05 | 9.95 |
KKR & Co. L.P. | 48.02 | NA | 2.81 | 3.55 | -0.04 | -0.01 | 0.01 | 21.54 |
BlackRock, Inc. | 20.58 | 20.58 | 13.91 | 35.03 | 0.12 | 0.03 | 0.03 | 251.57 |
Apollo Asset Management Inc | 8.99 | NA | 1.37 | 6.57 | -0.11 | -0.01 | 0.02 | 14.23 |
Brookfield Corp | 70.39 | 70.39 | NA | 3.84 | 0.02 | 0.02 | 0.01 | 25.54 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
TEKLA LIFE SCIENCES INVESTOR | NA | $357.7M | -27.37% | 5.75 | 0.0% |
Blackstone Inc | Buy | $104.4B | 167.61% | 107.3 | 14.46% |
KKR & Co. L.P. | Buy | $61.9B | 142.57% | 48.02 | -8.27% |
BlackRock, Inc. | Buy | $101.3B | 24.73% | 20.58 | 28.13% |
Apollo Asset Management Inc | Buy | $40.3B | 120.35% | 8.99 | -11.79% |
Brookfield Corp | Buy | $48.5B | -5.68% | 70.39 | 0.85% |
Corporate Announcements
TEKLA LIFE SCIENCES INVESTOR Dividends March,2023
In the quarter ending March,2023. TEKLA LIFE SCIENCES INVESTOR has declared dividend of $0.33
Read More
Company Information
tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form
Organization | TEKLA LIFE SCIENCES INVESTOR |
Employees | 0 |
CEO | Dr. Daniel R. Omstead M.S, Ph.D. |
Industry | Miscellaneous |
Discover More
DouYu International Holdings LTD
$1.04
+0.0%
Oppenheimer Ultra Dividend Revenue ETF
$39.53
+2.07%
FIRST BANCORP INC/ME
$27.87
+8.15%
AMMO INC
$2.04
+2.0%
REDHILL BIOPHARMA LTD-SP ADR
$2.05
+0.99%
Newmark Group, Inc.
$6.70
+7.2%
Arbutus Biopharma Corporation
$2.62
+0.77%
ALPS Clean Energy ETF
$45.16
+0.43%
WisdomTree SmallCap Earnings ETF
$45.10
+2.66%